Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
PF-04937319 - 3mg
PF-04937319 - 20mg
PF-04937319 - 50mg
PF-04937319 - 100mg
Sitagliptin - 100mg
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Phase 2, type 2 diabetes mellitus, PF-04937319
Eligibility Criteria
Inclusion Criteria:
- patients with type 2 diabetes, on metformin, age between 18-55 yrs, male or female
Exclusion Criteria:
- patients with type 1 diabetes, medically unstable, unacceptable clinical laboratory test results at screening
Sites / Locations
- Anaheim Clinical Trials
- National Research Institute
- Encompass Clinical Research
- The Family Doctors of Belleview
- Swiss Medical Research
- Renstar Medical Research
- Rockdale Medical Research Associates
- Solaris Clinical Research
- Central Kentucky Research Associates, Inc.
- Mount Sterling Clinic
- The Office of Dr. Matthew S. Barton, MD
- TKL Research, Inc.
- Rochester Clinical Research, Inc.
- Lillestol Research, LLC
- PriMed Clinical Research
- PriMed Physicians
- Lynn Health Science Institute
- Medical Research South, LLC
- Newton Family Medicine
- Austin Center for Clinical Research
- Texas Center for Drug Development, Inc.
- Plano Primary Care Clinic
- Pioneer Research Solutions, Inc.
- Martin Diagnostic Clinic
- DRC Kft.
- Dr. Rethy Pal Korhaz-Rendelointezet
- Qualiclinic Kft.
- Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
- Kenezy Korhaz Rendelointezet Egeszsegugyi Nonprofit Kft.
- Petz Aladar Megyei Oktato Korhaz
- Polgar es Tersege Egeszsegugyi Kozpont Nonprofit Zrt.
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
- Zala Megyei Korhaz
- Bhatia Hospital
- Seth G S Medical College & KEM Hospital, Dept of Endocrinology,
- Jehangir Clinical Development Centre Pvt. Ltd.
- S.R. Kalla Memorial Gastro and General Hospital
- Vicente Sotto Memorial Medical Center
- Institute for Studies on Diabetes Foundation Inc.
- The Medical City
- Spitalul Clinic Judetean de Urgenta Cluj-Napoca
- Institutul National de Diabet, Nutritie si Boli Metabolice Prof. Dr. N. Paulescu
- Institutul National de Diabet, Nutritie si Boli Metabolice Prof. Dr. N. Paulescu
- Metabolicke centrum MUDr. Katariny Raslovej, s.r.o.
- Medispektrum Plus, s.r.o.
- IN-DIA, s.r.o.
- MUDr. Zuzana Ochodnicka, Interna diabetologicka ambulancia, s.r.o.
- NOEMIS, s.r.o.
- DIABETOL, s.r.o.
- Areteus, s.r.o.
- Diabetes centrum, s.r.o.
- Bloemfontein Medi-Clinic
- Dr DR Lakha's Practice
- Midrand Medical Centre
- Medi-Clinic Heart Hospital
- Dr Bhana
- Dr JH Mynhardt
- Randles Road Medical Centre
- AA Mahomed Medical Centre
- Changhua Christian Hospital
- Far Eastern Memorial Hospital, Division of Endocrinology and Metabolism
- Taichung Veterans General Hospital, Division of Metabolism and Endocrinology
- Chi Mei Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Active Comparator
Arm Label
Placebo
PF-04937319 - Dose 1
PF-04937319 - Dose 2
PF-04937319 - Dose 3
PF-04937319 - Dose 4
Sitagliptin
Arm Description
Outcomes
Primary Outcome Measures
Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than (<) 6.5 percent (%) by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported.
Secondary Outcome Measures
Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4 and 8
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported.
Change From Baseline in Fasting Plasma Glucose at Week 1, 2, 4, 8, 12 and 14
Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used and data are presented in categories of <6.5 percent and <7 percent.
Number of Participants With Increase From Baseline Electrocardiogram (ECG)Data
Criteria for increase from baseline data: PR interval (percent change of greater than or equal to [>=] 25/50% [if baseline>200 then percent change of >25% counts; if baseline <=200 then percent change of >50% counts]; QRS complex (percent change of >=50%); QT Fridericia's correction (QTcF) interval (change of >=30 to <60 millisecond [msec], and change of >=60 msec).
Number of Participants With Increase/Decrease From Baseline Vital Signs Data
Participants who met the criteria for increase or decrease in vital signs data were reported. Criteria for increase or decrease from baseline vital signs data: sitting systolic blood pressure (BP) of >=30 millimeter of mercury (mmHg); sitting diastolic BP of >=20 mmHg and pulse rate was based on investigator's discretion.
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode
A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. HAE is defined as 1 of the given definitions: Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; or characteristic symptoms of HAE with home glucose monitoring measurement =< 70 milligram per deciliter (mg/dL) using ACCU-CHEK plasma-referenced home glucometers or =<74 mg/dL using International Federation of Clinical Chemistry (IFCC) referenced ACCU-CHEK or central laboratory glucometers; or any laboratory glucose value, meeting the following criterion with or without accompanying symptoms: =<49 mg/dL using ACCU-CHEK plasma-referenced home glucometers or =<53 mg/dL using IFCC referenced ACCU-CHEK or central laboratory glucometers.
Number of Hypoglycemic Events (HAE) Episodes Per Participant
A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Median number of events per participant was reported
Change From Baseline in Body Weight at Week 2, 4, 8, 12 and 14
Number of Participants With Abnormal Laboratory Values
Hemoglobin,hematocrit,red blood cells(RBC) count:less than [<]0.8*lower limit of normal[LLN],platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN],white blood cells(WBC):<0.6*LLN or >1.5*ULN,lymphocytes,total neutrophils:<0.8*LLN or >1.2*ULN, basophils,eosinophil,monocytes:>1.2*ULN;aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:>0.3*ULN,total protein,albumin:<0.8*LLN or >1.2*ULN;total bilirubin,direct bilirubin,indirect bilirubin:>1.5*ULN;triglycerides,cholesterol:>1.3*ULN, HDL:<0.8*LLN, LDL:>1.2*ULN,blood urea nitrogen,creatinine:>1.3*ULN,uric acid:>1.2*ULN;sodium: <0.95*LLN or >1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN or >1.1*ULN;creatine kinase:>2.0*ULN;glucose:<0.6*LLN or >1.5*ULN,urine WBC and RBC:>= 20/High Power Field [HPF]),urine epithelial cells (>=1 HPF),urine bacteria >20 high-powered field;qualitative urine glucose,urine blood to Hgb ratio (>=1);urine(protein,nitrite,mucus,leukocyte >=1 in urine dipstick test).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01475461
Brief Title
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Official Title
A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Phase 2, type 2 diabetes mellitus, PF-04937319
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
345 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
PF-04937319 - Dose 1
Arm Type
Experimental
Arm Title
PF-04937319 - Dose 2
Arm Type
Experimental
Arm Title
PF-04937319 - Dose 3
Arm Type
Experimental
Arm Title
PF-04937319 - Dose 4
Arm Type
Experimental
Arm Title
Sitagliptin
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
double-dummy placebo tablets administered once-daily for 84-days
Intervention Type
Drug
Intervention Name(s)
PF-04937319 - 3mg
Intervention Description
PF-04937319 3mg administered as tablets once-daily for 84-days
Intervention Type
Drug
Intervention Name(s)
PF-04937319 - 20mg
Intervention Description
PF-04937319 20mg administered as tablets once-daily for 84-days
Intervention Type
Drug
Intervention Name(s)
PF-04937319 - 50mg
Intervention Description
PF-04937319 50mg administered as tablets once-daily for 84-days
Intervention Type
Drug
Intervention Name(s)
PF-04937319 - 100mg
Intervention Description
PF-04937319 100mg administered as tablets once-daily for 84-days
Intervention Type
Drug
Intervention Name(s)
Sitagliptin - 100mg
Intervention Description
Sitagliptin 100mg administered as tablets once-daily for 84-days
Primary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 12
Description
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as less than (<) 6.5 percent (%) by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported.
Time Frame
Baseline (Day 1), Week 12
Secondary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Hemoglobin (HbA1C) at Week 2, 4 and 8
Description
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used. Change from baseline in percentage of HbA1c in participants were reported.
Time Frame
Baseline(Day 1), Week 2, 4, 8
Title
Change From Baseline in Fasting Plasma Glucose at Week 1, 2, 4, 8, 12 and 14
Time Frame
Baseline (Day 1), Week 1, 2, 4, 8, 12, 14
Title
Percentage of Participants Achieving Less Than 6.5 Percent and Less Than 7 Percent Glycosylated Hemoglobin (HbA1c) Levels at Week 12
Description
HbA1c is a form of hemoglobin which is measured primarily to identify the average glycemic control over prolonged periods of time. The normal range for the HbA1c test, was identified as <6.5 percent by the study-specific central laboratory used and data are presented in categories of <6.5 percent and <7 percent.
Time Frame
Week 12
Title
Number of Participants With Increase From Baseline Electrocardiogram (ECG)Data
Description
Criteria for increase from baseline data: PR interval (percent change of greater than or equal to [>=] 25/50% [if baseline>200 then percent change of >25% counts; if baseline <=200 then percent change of >50% counts]; QRS complex (percent change of >=50%); QT Fridericia's correction (QTcF) interval (change of >=30 to <60 millisecond [msec], and change of >=60 msec).
Time Frame
Baseline (Day 1) up to Week 14
Title
Number of Participants With Increase/Decrease From Baseline Vital Signs Data
Description
Participants who met the criteria for increase or decrease in vital signs data were reported. Criteria for increase or decrease from baseline vital signs data: sitting systolic blood pressure (BP) of >=30 millimeter of mercury (mmHg); sitting diastolic BP of >=20 mmHg and pulse rate was based on investigator's discretion.
Time Frame
Baseline (Day 1) up to Week 14
Title
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Description
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Time Frame
Baseline (Day 1) up to 14 days after last dose (up to 101 days)
Title
Percentage of Participants With at Least 1 Hypoglycemic Events (HAE) Episode
Description
A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. HAE is defined as 1 of the given definitions: Characteristic symptoms of HAE with no home glucose monitoring performed where clinical picture included prompt resolution with food intake, subcutaneous glucagon, or intravenous glucose; or characteristic symptoms of HAE with home glucose monitoring measurement =< 70 milligram per deciliter (mg/dL) using ACCU-CHEK plasma-referenced home glucometers or =<74 mg/dL using International Federation of Clinical Chemistry (IFCC) referenced ACCU-CHEK or central laboratory glucometers; or any laboratory glucose value, meeting the following criterion with or without accompanying symptoms: =<49 mg/dL using ACCU-CHEK plasma-referenced home glucometers or =<53 mg/dL using IFCC referenced ACCU-CHEK or central laboratory glucometers.
Time Frame
Baseline (Day 1) up to Week 14
Title
Number of Hypoglycemic Events (HAE) Episodes Per Participant
Description
A hypoglycemic event (HAE) was identified by characteristic symptoms or blood glucose levels. Median number of events per participant was reported
Time Frame
Baseline (Day 1) up to Week 14
Title
Change From Baseline in Body Weight at Week 2, 4, 8, 12 and 14
Time Frame
Baseline (Day 1), Week 2, 4, 8 , 12 , 14
Title
Number of Participants With Abnormal Laboratory Values
Description
Hemoglobin,hematocrit,red blood cells(RBC) count:less than [<]0.8*lower limit of normal[LLN],platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN],white blood cells(WBC):<0.6*LLN or >1.5*ULN,lymphocytes,total neutrophils:<0.8*LLN or >1.2*ULN, basophils,eosinophil,monocytes:>1.2*ULN;aspartate aminotransferase,alanine aminotransferase, alkaline phosphatase:>0.3*ULN,total protein,albumin:<0.8*LLN or >1.2*ULN;total bilirubin,direct bilirubin,indirect bilirubin:>1.5*ULN;triglycerides,cholesterol:>1.3*ULN, HDL:<0.8*LLN, LDL:>1.2*ULN,blood urea nitrogen,creatinine:>1.3*ULN,uric acid:>1.2*ULN;sodium: <0.95*LLN or >1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN or >1.1*ULN;creatine kinase:>2.0*ULN;glucose:<0.6*LLN or >1.5*ULN,urine WBC and RBC:>= 20/High Power Field [HPF]),urine epithelial cells (>=1 HPF),urine bacteria >20 high-powered field;qualitative urine glucose,urine blood to Hgb ratio (>=1);urine(protein,nitrite,mucus,leukocyte >=1 in urine dipstick test).
Time Frame
Baseline (Day 1) up to Week 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with type 2 diabetes, on metformin, age between 18-55 yrs, male or female
Exclusion Criteria:
patients with type 1 diabetes, medically unstable, unacceptable clinical laboratory test results at screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Anaheim Clinical Trials
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Encompass Clinical Research
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978
Country
United States
Facility Name
The Family Doctors of Belleview
City
Belleview
State/Province
Florida
ZIP/Postal Code
34420
Country
United States
Facility Name
Swiss Medical Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Renstar Medical Research
City
Ocala
State/Province
Florida
ZIP/Postal Code
34471
Country
United States
Facility Name
Rockdale Medical Research Associates
City
Conyers
State/Province
Georgia
ZIP/Postal Code
30094
Country
United States
Facility Name
Solaris Clinical Research
City
Meridian
State/Province
Idaho
ZIP/Postal Code
83646
Country
United States
Facility Name
Central Kentucky Research Associates, Inc.
City
Mount Sterling
State/Province
Kentucky
ZIP/Postal Code
40353
Country
United States
Facility Name
Mount Sterling Clinic
City
Mount Sterling
State/Province
Kentucky
ZIP/Postal Code
40353
Country
United States
Facility Name
The Office of Dr. Matthew S. Barton, MD
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89144
Country
United States
Facility Name
TKL Research, Inc.
City
Paramus
State/Province
New Jersey
ZIP/Postal Code
07652
Country
United States
Facility Name
Rochester Clinical Research, Inc.
City
Rochester
State/Province
New York
ZIP/Postal Code
14609
Country
United States
Facility Name
Lillestol Research, LLC
City
Fargo
State/Province
North Dakota
ZIP/Postal Code
58103
Country
United States
Facility Name
PriMed Clinical Research
City
Kettering
State/Province
Ohio
ZIP/Postal Code
45429
Country
United States
Facility Name
PriMed Physicians
City
Kettering
State/Province
Ohio
ZIP/Postal Code
45429
Country
United States
Facility Name
Lynn Health Science Institute
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
Facility Name
Medical Research South, LLC
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Facility Name
Newton Family Medicine
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Facility Name
Austin Center for Clinical Research
City
Austin
State/Province
Texas
ZIP/Postal Code
78756
Country
United States
Facility Name
Texas Center for Drug Development, Inc.
City
Houston
State/Province
Texas
ZIP/Postal Code
77081
Country
United States
Facility Name
Plano Primary Care Clinic
City
Plano
State/Province
Texas
ZIP/Postal Code
75024
Country
United States
Facility Name
Pioneer Research Solutions, Inc.
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77479
Country
United States
Facility Name
Martin Diagnostic Clinic
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Facility Name
DRC Kft.
City
Balatonfured
ZIP/Postal Code
8230
Country
Hungary
Facility Name
Dr. Rethy Pal Korhaz-Rendelointezet
City
Bekescsaba
ZIP/Postal Code
5600
Country
Hungary
Facility Name
Qualiclinic Kft.
City
Budapest
ZIP/Postal Code
1036
Country
Hungary
Facility Name
Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
City
Debrecen
ZIP/Postal Code
4032
Country
Hungary
Facility Name
Kenezy Korhaz Rendelointezet Egeszsegugyi Nonprofit Kft.
City
Debrecen
ZIP/Postal Code
4043
Country
Hungary
Facility Name
Petz Aladar Megyei Oktato Korhaz
City
Gyor
ZIP/Postal Code
9023
Country
Hungary
Facility Name
Polgar es Tersege Egeszsegugyi Kozpont Nonprofit Zrt.
City
Polgar
ZIP/Postal Code
4090
Country
Hungary
Facility Name
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
City
Szeged
ZIP/Postal Code
6720
Country
Hungary
Facility Name
Zala Megyei Korhaz
City
Zalaegerszeg
ZIP/Postal Code
8900
Country
Hungary
Facility Name
Bhatia Hospital
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400 007
Country
India
Facility Name
Seth G S Medical College & KEM Hospital, Dept of Endocrinology,
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400 012
Country
India
Facility Name
Jehangir Clinical Development Centre Pvt. Ltd.
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411001
Country
India
Facility Name
S.R. Kalla Memorial Gastro and General Hospital
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302001
Country
India
Facility Name
Vicente Sotto Memorial Medical Center
City
Cebu City
ZIP/Postal Code
6000
Country
Philippines
Facility Name
Institute for Studies on Diabetes Foundation Inc.
City
Marikina City
ZIP/Postal Code
1810
Country
Philippines
Facility Name
The Medical City
City
Pasig City
ZIP/Postal Code
1605
Country
Philippines
Facility Name
Spitalul Clinic Judetean de Urgenta Cluj-Napoca
City
Cluj-Napoca
State/Province
Jud. Cluj
ZIP/Postal Code
400006
Country
Romania
Facility Name
Institutul National de Diabet, Nutritie si Boli Metabolice Prof. Dr. N. Paulescu
City
Bucuresti
ZIP/Postal Code
011234
Country
Romania
Facility Name
Institutul National de Diabet, Nutritie si Boli Metabolice Prof. Dr. N. Paulescu
City
Bucuresti
ZIP/Postal Code
020475
Country
Romania
Facility Name
Metabolicke centrum MUDr. Katariny Raslovej, s.r.o.
City
Bratislava
ZIP/Postal Code
831 01
Country
Slovakia
Facility Name
Medispektrum Plus, s.r.o.
City
Bratislava
ZIP/Postal Code
851 01
Country
Slovakia
Facility Name
IN-DIA, s.r.o.
City
Lucenec
ZIP/Postal Code
984 01
Country
Slovakia
Facility Name
MUDr. Zuzana Ochodnicka, Interna diabetologicka ambulancia, s.r.o.
City
Nitra
ZIP/Postal Code
949 01
Country
Slovakia
Facility Name
NOEMIS, s.r.o.
City
Nove Mesto nad Vahom
ZIP/Postal Code
915 01
Country
Slovakia
Facility Name
DIABETOL, s.r.o.
City
Presov
ZIP/Postal Code
080 01
Country
Slovakia
Facility Name
Areteus, s.r.o.
City
Trebisov
ZIP/Postal Code
075 01
Country
Slovakia
Facility Name
Diabetes centrum, s.r.o.
City
Trencin
ZIP/Postal Code
911 01
Country
Slovakia
Facility Name
Bloemfontein Medi-Clinic
City
Bloemfontein
State/Province
Free State
ZIP/Postal Code
9301
Country
South Africa
Facility Name
Dr DR Lakha's Practice
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1829
Country
South Africa
Facility Name
Midrand Medical Centre
City
Midrand
State/Province
Gauteng
ZIP/Postal Code
1685
Country
South Africa
Facility Name
Medi-Clinic Heart Hospital
City
Pretoria
State/Province
Gauteng
ZIP/Postal Code
0083
Country
South Africa
Facility Name
Dr Bhana
City
Waverley
State/Province
Gauteng
ZIP/Postal Code
2090
Country
South Africa
Facility Name
Dr JH Mynhardt
City
Kimberley
State/Province
Northern Cape
ZIP/Postal Code
8301
Country
South Africa
Facility Name
Randles Road Medical Centre
City
Durban
ZIP/Postal Code
4091
Country
South Africa
Facility Name
AA Mahomed Medical Centre
City
Moloto
ZIP/Postal Code
1022
Country
South Africa
Facility Name
Changhua Christian Hospital
City
Changhua City
ZIP/Postal Code
500
Country
Taiwan
Facility Name
Far Eastern Memorial Hospital, Division of Endocrinology and Metabolism
City
New Taipei City
ZIP/Postal Code
220
Country
Taiwan
Facility Name
Taichung Veterans General Hospital, Division of Metabolism and Endocrinology
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Facility Name
Chi Mei Medical Center
City
Tainan
ZIP/Postal Code
710
Country
Taiwan
12. IPD Sharing Statement
Citations:
PubMed Identifier
25885172
Citation
Amin NB, Aggarwal N, Pall D, Paragh G, Denney WS, Le V, Riggs M, Calle RA. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. doi: 10.1111/dom.12474. Epub 2015 May 11.
Results Reference
derived
Links:
URL
https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1621007&StudyName=Phase%202%20Study%20To%20Evaluate%20Safety%20And%20Efficacy%20Of%20Investigational%20Drug%20-%20PF04937319%20In%20Patients%20With%20Type%202%20Diabetes
Description
To obtain contact information for a study center near you, click here.
Learn more about this trial
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs